BRAF and myelodysplastic syndrome: In some cases, the effects of APR-246 have been examined in combination with azacitidine (in MDS and AML), dabrafenib (in V600 BRAF-mutant melanomas), pembrolizumab (an immunotherapeutic which targets PD-1, also known as Keytruda), and venetoclax [15,59,60,61,62].